The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1741
ISSUE 1741
November 10, 2025
Issue 1741
- Aceclidine (Vizz) for Presbyopia
- Sulopenem Etzadroxil/Probenecid (Orlynvah) for Uncomplicated UTIs
- Garadacimab (Andembry) for Hereditary Angioedema Prophylaxis
- In Brief: Updates for Lecanemab (Leqembi) for Alzheimer's Disease
- In Brief: Primary Aldosteronism Screening in Patients with Hypertension
- In Brief: Keytruda Qlex – A Subcutaneous Formulation of Pembrolizumab (online only)
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Aceclidine (Vizz) for Presbyopia
November 10, 2025 (Issue: 1741)
The FDA has approved Vizz (Lenz Therapeutics), a
1.44% ophthalmic solution of the cholinergic agonist
aceclidine, for treatment of presbyopia in adults.
Aceclidine has been available in the EU for years for
treatment of open-angle...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
